Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

被引：75

作者：

Ashcroft, AJ ^{[1
]}

Davies, FE ^{[1
]}

Morgan, GJ ^{[1
]}

机构：

[1] Univ Leeds, Epidemiol & Genet Unit, Leeds LS2 9JT, W Yorkshire, England

来源：

LANCET ONCOLOGY | 2003年 / 4卷 / 05期

关键词：

D O I：

10.1016/S1470-2045(03)01076-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Osteolytic bone disease is a major cause of morbidity in patients with multiple myeloma. Our understanding of the pathophysiology of multiple myeloma has increased substantially during the past decade. However the underlying mechanisms of bone destruction and the treatments available have, until recently, received relatively little specific attention. In this review, we provide an overview of the RANK/RANKL/osteoprotegerin system; we describe its interaction with other cellular mechanisms, through which malignant plasma cells drive osteolysis, and explain how bisphosphonates can be used to block this action. We also review the supporting evidence for bisphosphonates as the treatment of choice for patients with bone complications related to multiple myeloma, and discuss possible developments for targeted therapy in the future.

引用

页码：284 / 292

页数：9

共 75 条

[1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].

Abe, M ;

Hiura, K ;

Wilde, J ;

Moriyama, K ;

Hashimoto, T ;

Ozaki, S ;

Wakatsuki, S ;

Kosaka, M ;

Kido, S ;

Inoue, D ;

Matsumoto, T .

BLOOD, 2002, 100 (06) :2195-2202

[2] In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J].

Aparicio, A ;

Gardner, A ;

Tu, Y ;

Savage, A ;

Berenson, J ;

Lichtenstein, A .

LEUKEMIA, 1998, 12 (02) :220-229

[3] Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells [J].

Barille, S ;

Akhoundi, C ;

Collette, M ;

Mellerin, MP ;

Rapp, MJ ;

Harousseau, JL ;

Bataille, R ;

Amiot, M .

BLOOD, 1997, 90 (04) :1649-1655

[4] SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS [J].

BATAILLE, R ;

JOURDAN, M ;

ZHANG, XG ;

KLEIN, B .

JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) :2008-2011

[5]

Bellamy WT, 1999, CANCER RES, V59, P728

[6] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[7]

Berenson JR, 2001, SEMIN ONCOL, V28, P25

[8] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, MJ ;

Blacklock, HA ;

Bell, R ;

Simeone, J ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493

[9] Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, M ;

Blacklock, H ;

Bell, R ;

Simeone, JF ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602

[10]

Boissier S, 2000, CANCER RES, V60, P2949

← 1 2 3 4 5 6 7 8 →